Literature DB >> 26066683

The L-arginine/NO pathway and homoarginine are altered in Duchenne muscular dystrophy and improved by glucocorticoids.

Irina Hörster1, Katharina Weigt-Usinger, Christina Carmann, Kristine Chobanyan-Jürgens, Cornelia Köhler, Ulrike Schara, Arslan Arinc Kayacelebi, Bibiana Beckmann, Dimitrios Tsikas, Thomas Lücke.   

Abstract

The L-arginine/nitric oxide (L-Arg/NO) pathway regulates endothelial function and may play an important role in the pathogenesis of Duchenne muscular dystrophy (DMD). Yet, this pathway is poorly investigated in children suffering from DMD. Endothelial dysfunction can affect the perfusion of contracting muscles, thus leading to ischemia and hypoxia. In the present study, we tested the hypothesis that reduced NO production due to elevated synthesis of N (G),N (G)-dimethyl-L-arginine (asymmetric dimethylarginine, ADMA), an endogenous inhibitor of NO synthesis, is a possible pathophysiological mechanism for progressive intramuscular muscle ischemia and disturbed endothelial function in children with DMD. Given the possible antagonistic action of homoarginine (hArg) on ADMA, we also analyzed this amino acid. We investigated 55 male patients with DMD and 54 healthy male controls (HC; aged 11.9 ± 4.8 vs. 11.1 ± 4.9 years, mean ± SD). Urinary creatinine and metabolites of the L-Arg/NO pathway were measured in plasma and urine by GC-MS or GC-MS/MS. Urine levels of ADMA and its major urinary metabolite dimethylamine (DMA), nitrite and nitrate (P < 0.001 for all) and hArg (P = 0.002) were significantly higher in DMD patients compared to HC, while the urinary DMA/ADMA molar ratio was lower (P = 0.002). In plasma, nitrate (P < 0.001), hArg (P = 0.002) and the hArg/ADMA ratio (P < 0.001) were lower in DMD than in HC. In plasma, ADMA (631 ± 119 vs. 595 ± 129 nM, P = 0.149), arginine and nitrite did not differ between DMD and HC. In DMD, positive correlations between ADMA, DMA or nitrate excretion and the stage of disease (according to Vignos and Thompson) were found. In DMD patients on steroid medication, lower concentrations of ADMA in plasma, and of DMA, ADMA, nitrate and hArg in urine were observed compared to non-treated patients. The L-Arg/NO pathway is impaired in DMD patients, with the disease progression being clinically negatively correlated with the extent of impairment. One of the underlying mechanisms in DMD may involve insufficient antagonism of ADMA by hArg. Steroids, but not creatine supplementation, seems to improve the L-Arg/NO pathway in DMD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26066683     DOI: 10.1007/s00726-015-2018-x

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  12 in total

Review 1.  Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials.

Authors:  Pierre G Carlier; Benjamin Marty; Olivier Scheidegger; Paulo Loureiro de Sousa; Pierre-Yves Baudin; Eduard Snezhko; Dmitry Vlodavets
Journal:  J Neuromuscul Dis       Date:  2016-03-03

2.  Dystrophinopathy-associated dysfunction of Krebs cycle metabolism.

Authors:  Angus Lindsay; Christopher M Chamberlain; Bruce A Witthuhn; Dawn A Lowe; James M Ervasti
Journal:  Hum Mol Genet       Date:  2019-03-15       Impact factor: 6.150

3.  Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans.

Authors:  Guoyao Wu; Cynthia J Meininger; Catherine J McNeal; Fuller W Bazer; J Marc Rhoads
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Asymmetric Dimethylarginine and Its Relation As a Biomarker in Nephrologic Diseases.

Authors:  Mustafa E Sitar
Journal:  Biomark Insights       Date:  2016-12-07

5.  Circulating Biomarkers for Duchenne Muscular Dystrophy.

Authors:  Annemieke Aartsma-Rus; Pietro Spitali
Journal:  J Neuromuscul Dis       Date:  2015-07-22

6.  Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.

Authors:  Patricia Hafner; Ulrike Bonati; Daniela Rubino; Vanya Gocheva; Thomas Zumbrunn; Nuri Gueven; Dirk Fischer
Journal:  Trials       Date:  2016-08-03       Impact factor: 2.279

7.  Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study.

Authors:  Patricia Hafner; Ulrike Bonati; Beat Erne; Maurice Schmid; Daniela Rubino; Urs Pohlman; Thomas Peters; Erich Rutz; Stephan Frank; Cornelia Neuhaus; Stefanie Deuster; Monika Gloor; Oliver Bieri; Arne Fischmann; Michael Sinnreich; Nuri Gueven; Dirk Fischer
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

8.  Forskolin attenuates doxorubicin-induced accumulation of asymmetric dimethylarginine and s-adenosylhomocysteine via methyltransferase activity in leukemic monocytes.

Authors:  Sandhiya Ramachandran; Swetha Loganathan; Vinnie Cheeran; Soniya Charles; Ganesh Munuswamy-Ramanujan; Mohankumar Ramasamy; Vijay Raj; Kanchana Mala
Journal:  Leuk Res Rep       Date:  2018-02-23

Review 9.  Urinary Dimethylamine (DMA) and Its Precursor Asymmetric Dimethylarginine (ADMA) in Clinical Medicine, in the Context of Nitric Oxide (NO) and Beyond.

Authors:  Dimitrios Tsikas
Journal:  J Clin Med       Date:  2020-06-12       Impact factor: 4.241

10.  Muscle metabolomics analysis reveals potential biomarkers of exercise‑dependent improvement of the diaphragm function in chronic obstructive pulmonary disease.

Authors:  Jian Li; Yufan Lu; Ning Li; Peijun Li; Jianqing Su; Zhengrong Wang; Ting Wang; Zhaoyu Yang; Yahui Yang; Haixia Chen; Lu Xiao; Hongxia Duan; Weibing Wu; Xiaodan Liu
Journal:  Int J Mol Med       Date:  2020-03-12       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.